Get the Stockscreener App
3.12
3.41%
-0.11
After Hours:
3.13
0.010
+0.32%
Ardelyx Inc stock is traded at $3.12, with a volume of 6.87M.
It is down -3.41% in the last 24 hours and down -12.85% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$3.23
Open:
$3.2
24h Volume:
6.87M
Relative Volume:
1.45
Market Cap:
$805.55M
Revenue:
$427.68M
Net Income/Loss:
$-58.06M
P/E Ratio:
-13.10
EPS:
-0.2382
Net Cash Flow:
$-37.50M
1W Performance:
-5.74%
1M Performance:
-12.85%
6M Performance:
-50.71%
1Y Performance:
-37.72%
1-Day Range:
$3.09
$3.205
1-Week Range:
$3.09
$3.35
52-Week Range:
$3.09
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
3.12 | 805.55M | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-26 | Resumed | Ladenburg Thalmann | Buy |
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL - GlobeNewswire Inc.
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionARDX - GlobeNewswire Inc.
New Strong Sell Stocks for October 9th - Zacks Investment Research
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionARDX - GlobeNewswire Inc.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
SueWallSt Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026ARDX - Morningstar
SueWallSt Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026ARDX - TradingView
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit - PR Newswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ARDX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026 - FinancialContent
ARDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Ardelyx, Inc. Securities LawsuitContact Levi & Korsinsky - PR Newswire
New Strong Sell Stocks for October 7th - Zacks Investment Research
Ardelyx Inc (41X.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) - The National Law Review
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Baidu, Inc. (BIDU), Ardelyx, Inc. (ARDX), and Better Home & Finance Holding Company (BETR) Announced by Holzer & Holzer, LLC - GlobeNewswire Inc.
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Securities Lawsuit Alert: Ardelyx, Inc. (ARDX) InvestorsContact Levi & Korsinsky Before November 16, 2026 - ACCESS Newswire
Class Action Lawsuit Filed: Ardelyx, Inc. (ARDX)Join by November 16, 2026Contact Levi & Korsinsky - ACCESS Newswire
Ardelyx to present hyperphosphatemia research at ASN meeting By Investing.com - Investing.com Nigeria
Ardelyx to present hyperphosphatemia research at ASN meeting By Investing.com - Investing.com South Africa
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionARDX - GlobeNewswire Inc.
Ardelyx to present hyperphosphatemia research at ASN meeting - Investing.com
ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice – Contact Levi & Korsinsky - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Important Notice to Long-Term Shareholders of Anavex Life - GlobeNewswire
Many of about 550,000 U.S. dialysis patients have high blood phosphate. Ardelyx will present three studies. - Stock Titan
Robbins LLP Urges ARDX Stockholders Who Lost Money Investing in Ardelyx, Inc. to Contact the Firm for Information About Leading the Class Action - FinancialContent
Ardelyx Inc (41X.HM) Income Statement - Yahoo! Finance Canada
Ardelyx (NasdaqGM:ARDX) Stock Forecast & Analyst Predictions - Simply Wall Street
Ardelyx Inc (41X.HM) stock historical prices and data - Yahoo Finance UK
Ardelyx Inc. R (41X.HM) Q1 FY2026 earnings call transcript - Yahoo Finance
Ardelyx Inc. R (41X.HM) Q4 FY2025 earnings call transcript - Yahoo Finance
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionARDX - GlobeNewswire Inc.
Is Ardelyx (ARDX) Undervalued Following Its PM360 Trailblazer Awards? - Simply Wall Street
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Ardelyx Inc (41X.HM) interactive stock chart - Yahoo Finance UK
Ardelyx Inc (41X.HM) income statement - Yahoo Finance UK
November 16, 2026 Deadline Approaching: Join Class Action Against Ardelyx, Inc. (ARDX)Contact Levi & Korsinsky - ACCESS Newswire
ARDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (AR - The National Law Review
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026 - TradingView
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026 - PR Newswire
ARDX UPCOMING DEADLINE: Levi & Korsinsky Alerts Ardelyx, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
A podcast on gut disorders wins gold at the PM360 awards - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in XTI Aerospace, Inc. of Class Action Lawsuit and Upcoming Deadlines – XTIA - GlobeNewswire Inc.
Debt to equity ratio of Ardelyx, Inc. – HAN:41X - TradingView
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ardelyx Inc Stock (ARDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Foster Eric Duane | Officer |
Aug 21 '26 |
Proposed Sale |
4.03 |
11,900 |
47,957 |
0 |
| Bishop John E | Officer |
Aug 21 '26 |
Proposed Sale |
4.03 |
25,500 |
102,765 |
0 |
| Brady James Parker | Officer |
Aug 21 '26 |
Proposed Sale |
4.03 |
19,700 |
79,391 |
0 |
| Brady James Parker | Chief Human Resources Officer |
Aug 21 '26 |
Sale |
3.86 |
15,136 |
58,378 |
245,930 |
| Foster Eric Duane | Chief Commercial Officer |
Aug 21 '26 |
Sale |
3.86 |
8,562 |
33,023 |
409,410 |
| Kelliher Mike | Chief Business Officer |
Aug 21 '26 |
Sale |
3.86 |
7,758 |
29,922 |
349,660 |
| Williams Laura A | Chief Patient Officer |
Aug 21 '26 |
Sale |
3.86 |
10,739 |
41,419 |
367,456 |
| RAAB MICHAEL | President & CEO |
Aug 21 '26 |
Sale |
3.86 |
58,574 |
225,914 |
1,619,792 |
| Hohenleitner Susan | Officer |
Aug 21 '26 |
Proposed Sale |
4.03 |
2,650 |
10,680 |
0 |
| Reilly Joseph James | See Remarks |
Aug 21 '26 |
Sale |
3.86 |
3,982 |
15,358 |
145,854 |
3.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):